Stem Cell Therapy for Stroke
He is a known case of CVA since July 2010, leading to left sided hemiplegia with speech involvement. On MRI Brain, it was seen to be right MCA infarct. He was managed conservatively and has been undergoing regular rehabilitation since then. Neurologically, he is hypertonic and hyperreflexic. On examination: he has left sided paraesthesia (abnormal sensation). He has near normal left lower extremities voluntary control, but poor voluntary control of left hand, but fair control over left (proximal) upper extremities mainly shoulder and elbow. He has near normal cognition and speech. He has affected fine motor control and gross balance while walking. He has hemiplegic gait. Functionally, he is independent in most ADL and mobility. After Stem Cell Therapy 1) Now grasp of left hand has improved. Can hold glass with minimal assistance and drink water. Earlier could not hold glass. 2) Now uses his left hand more in activities -- drinking water. Earlier it was not possible to drink water and use left hand but now he can. 3) Stiffness in left upper limb reduced. 4) Can now sleep on left side also. Earlier would pain a lot. 5) Now he doesn #39;t require help while putting his pant hooks/buttons (but only in certain pants, which are not tight). Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in www ...

By: neurogenbsi

Read the original post:
Stem Cell Therapy for Stroke - Video

Stem Cell Therapy for Spinal Cord Injury c5 - c6
He has history of fall in the swimming pool ,leading to fracture and compression of C4 over C5 and Quadriplegia with complete bowel bladder incontinence . He was operated for C5 corpectomy spiral stabilization. He is on regular rehabilitation since then. Neurologically, he is hypertonic hyperreflexic On examination, he has partial sensory recovery till D1, but complete loss below D1 .He has grade 0 muscle power in bilateral lower extremity wrist below, but grade 3++ muscle power in bilateral shoulders. He has no bowel bladder control is on condom catheter for same on ASIA impairment scale he scores #39;A #39; Functionally, he is dependent for all ADL will chair bound for mobility. On FIM he scores 73 After Stem Cell Therapy 1) Trunk balance has improved in sitting and standing. 2) Touch sensation has improved (10%). 3) Now while standing and exercising, can feel stress coming on joint (proprioception). 4) Spasticity, flexor spasms in lower limb increased. 5) Left thumb movement has started. 6) FIM -- no change. 7) Now spasticity grade 2 to 3. 8) Walking in parallel bars better. Can turn and find it easier than before. Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Read more:
Stem Cell Therapy for Spinal Cord Injury c5 - c6 - Video

Stem Cell Therapy for Moderate Mental Retardation with Behavioural Issues
She is a known case of Mental Retardation with history of full term normal delivery, but mother had malaria during pregnancy. She had delayed motor milestones but achieved. She had delay mainly in speech. So she was tested and diagnosed to have MR. Gradually, she developed abnormal behavior and hyperactivity. Neurologically, she has near normal tone, reflexes and muscle power. On examination: She is hyperactive. She has poor social interaction and poor social skills. She has poor attention span. She has aggressive behavior. She is unable to read and write, but goes to a special school. She is unable to follow commands and has delayed speech. She needs assistance in all ADL. After Stem Cell Therapy OT assessment: 1) Hyperactivity has reduced by 30-40%. Now she can sit at one place if activity is of interest for 1-2 hours. She has calmed down a lot. 2) Attention and concentration has improved. Now she follows commands or instructions given. Does not need repetitions. 3) Concepts have improved, recognizes objects, matching colours, alphabets, numbers. 4) Speech is clearer and responses are relevant to questions asked. She sometimes still has repetitive speech or speaks sentences not appropriate to the present situations. 5) Aggressive behaviours have decreased. Initially the first month after SCT -- she showed increased aggressiveness towards younger brother. She would beat her brother for no reason. That slowly reduced. Now rarely does it (only when very angry). 6 ...

By: neurogenbsi

Read the rest here:
Stem Cell Therapy for Moderate Mental Retardation with Behavioural Issues - Video

Stem Cell Therapy for Cerebral Palsy
She is a known case of CP with history of full term normal delivery, with birth weight approximately 2.4 kg. But gradually as she grew parents noticed she had delayed motor milestones, so she was tested and diagnosed to have CP. Cause for it was suspected to be maternal TORCH infection during pregnancy. She has been on regular rehabilitation and has also had Botox injections twice. Neurologically, she is hypertonic and hyperreflexic. On examination: she has poor voluntary control of bilateral lower extremities, but near normal upper extremities voluntary control. But her grip is slightly poor. She has slurred speech and near normal bowel bladder control. She has fair oromotor control. Functionally, she needs assistance in all ADL and mobility. She is able to walk with AFOs for short distances. On WeeFIM she scores 57. After Stem Cell Therapy OT assessment: 1) Now able to walk with walker. Shifts weights of pelvis. 2) Stamina has increased. Exercise tolerance has increased. 3) Trunk balance has improved. 4) Now stepping is better, now lifts leg while stepping. 5) Standing without holding for about 50 counts. 6) Fear of falling has reduced. 7) Tightness in LL has reduced. 8) Catching ball is better. 9) Back extensor has improved. 10) Can come on bed without support of wall to get a thrust. 11) FIM improved from 60 to 65 secondary to bathing, dressing. 12) Now uses a potty seat over commode, sits independently. Assessment by Speech Therapist: 1) Loudness has improved. 2 ...

By: neurogenbsi

More:
Stem Cell Therapy for Cerebral Palsy - Video

Stem Cell Therapy for Left Hemiplegia Stroke
He is a case of right MCA infarct with left hemiplegia since 2009. He was treated conservatively and is able to walk independently, but not able to use left upper extremity. Neurologically, he is hypertonic and hyperreflexic on the left side. On examination: he has grade 3 voluntary control in left lower extremity and walks with aid of a stick. He has hemiplegic gait. Left upper limb voluntary control is poor with spaticity grade 3 in shoulder. On Modified Ashworth Scale spasticity on left side is grade 4. He has normal speech and bowel /bladder control. After Stem Cell Therapy 1) Spasticity has reduced in all muscle of left UE and LE. 2) He can raise his left shoulder upto 100° of range which he couldn #39;t do before. 3) Previously, he used to stretch his left hand only in the morning but now he can do the same throughout the day. 4) He can climb stairs without any support. 5) Balance while standing, walking and stair climbing has improved. 6) Now he can maintain tandem stance for 20 sec without losing balance. 7) He can do marching with leg in standing which he couldn #39;t do before. 8) VC grading : elbow 3 knee 4 Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Originally posted here:
Stem Cell Therapy for Left Hemiplegia Stroke - Video

Lecture on genetic engineering of grapes The Sheridan Press (subscription) SHERIDAN — Sadanand Dhekney, Assistant Professor of Horticulture at University of Wyoming, will present a lecture on the “Genetic Engineering of Grapes for Enhanced Drought and Salt Tolerance.” The talk will be Jan. 30 from 7-8 p.m. at the Science ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEiwScU7wVSrAsGHPhR15OYP6q1Zg&url=http://www.thesheridanpress.com/news/lecture-on-genetic-engineering-of-grapes/article_e4abed94-64c2-11e2-8992-001a4bcf6878.html

Alabaster's business growth may come from biotechnology firms al.com (blog) Alabaster Industrial Development Board Executive Director Cam Ward says major distribution centers as well as biotechnology firms are sources of anticipated business growth for the area. ALABASTER, Alabama -- Alabaster Industrial Development Board ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHDqkjmLGN4GO8B2NMCU0JCMzImWA&url=http://blog.al.com/spotnews/2013/01/alabasters_business_growth_may.html

HudsonAlpha Institute for Biotechnology offers Alabama teachers, students ... The Huntsville Times - al.com (blog) HUNTSVILLE, Alabama -- Deadlines are approaching for teacher education and student internships offered by the HudsonAlpha Institute for Biotechnology. The Huntsville institute is a leading center for genetic research and education and hosts a number of ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNE6lsrWR_hcCtzBS97KTb4xj6sVYA&url=http://blog.al.com/breaking/2013/01/hudsonalpha_institute_for_biot_6.html

BBC News

In pictures: Biotechnology is engineering the world BBC News In pictures: Biotechnology is engineering the world. Fluorescent transgenic mouse Biotechnology is the use of living organisms to produce useful products. This mouse glows green under UV light as it contains a special fluorescent gene from a jellyfish ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGi76e6WlRAMVBoeMR4nLOdW1g9OA&url=http://www.bbc.co.uk/news/in-pictures-21121325

Research and Markets: USA Directory of Biotechnology Companies 2013 - 2000 ... Fort Mills Times The USA Directory of Biotechnology Companies 2012-13 is one of the most comprehensive and accurate Directory of companies and executives in the biotechnology industry that have ever been published. It contains more than 2,000 biotechnology ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGR6cj8H1cO--26RdmFdqlUJv0GCA&url=http://www.fortmilltimes.com/2013/01/25/2456945/research-and-markets-usa-directory.html

Western Farm Press

Cotton biotechnology award recipients announced Western Farm Press As part of the Plant and Animal Genomic Conference held in San Diego, Calif., Dr. Don Jones of Cotton Incorporated presented the 2012 Cotton Biotechnology Award to five outstanding researchers that were instrumental in mapping the cotton genome.

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNE0lgHDaCSnT52hTrNbmOe2BRWhzQ&url=http://westernfarmpress.com/cotton/cotton-biotechnology-award-recipients-announced

World's Largest Biotechnology Company Uses Team of 74 Lobbyists to Win ... AllGov Amgen, Inc., the world's largest biotechnology firm, will continue to sell one of its best selling drugs at unregulated prices, thanks to a provision buried within the fiscal-cliff compromise. With the help of its corps of 74 lobbyists, Amgen convinced ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGGrWUdogilZj0ZkZbj-X1kvstrOQ&url=http://www.allgov.com/news/where-is-the-money-going/worlds-largest-biotechnology-company-uses-team-of-74-lobbyists-to-win-fiscal-cliff-gift-130122?news%3D846825

Research on human beings has expanded greatly due to progress and the evolution of society as well as customs. Not only the unceasing development of research on human beings, but also interference in the beginning and end of life with homologous and heterogonous human reproduction, surrogate motherhood, cloning, gene therapies, eugenics,euthanasia, dysthanasia, orthothanasia, assisted suicide, genetic engineering, reassignment surgery in cases of transsexuality, the use of recombinant DNA technology and embryonic stem cells, transplantation of human organs and tissues, biotechnology and many other scientific advances. Scientific progress goes faster than the real needs of human beings, who are the final recipient of the entire evolutionary progress. Hence, there is the need to scrutinize w...

Source:
http://www.medworm.com/index.php?rid=6986259&cid=c_449_19_f&fid=37449&url=http%3A%2F%2Fwww.scielo.br%2Fscielo.php%3Fscript%3Dsci_arttext%26pid%3DS1516-84842012000600016%26lng%3Den%26nrm%3Diso%26tlng%3Den

The California stem cell agency today
issued a press release touting “dramatic changes” at the agency in response to critical recommendations by the Institute of Medicine.

• “The 13 Board members appointed from
  institutions eligible for funding from the stem cell agency, such as
  those in the University of California system, would no longer vote on
  any grants brought before the Board but would instead abstain
• “All members of the Board would
  be able to participate in discussions on applications but only
  patient advocates and independent members of the Board would be able
  to vote on funding issues (members would continue to refrain from
  any discussion of specific applications from their institutions)
• “Patient Advocates would
  continue to be members of the Grants Working Groups but would not
  vote on individual applications
• “Programmatic review, aimed at
  balancing the agency’s portfolio, would take place at public Board
  meetings where members have a chance to make changes to
  recommendations from the Grants Working Group
• “Industry involvement would
  increase, where appropriate, on the Grants Working Group, and also
  feature in a newly constituted Scientific Advisory Board; the
  structure and membership of this group is still under discussion
• “Appeals on applications not
  recommended for funding will be handled by science staff who will
  evaluate them, determine if they merit further review by the Grants
  Working Group, and ultimately make recommendations to the Board.
  Staff will also be allowed to advocate for additional grants not
  recommended for funding by the Grants Working Group that they
  believe should be considered in programmatic review
• “The Chair and President would
  share a division of responsibilities with the President supervising
  all scientific operations and internal operational responsibilities.
  In addition the Chief Financial Officer would report to the
  President. The Chair would handle the ‘external affairs’ aspect
  of the agency, things such as financial sustainability to raise
  additional funds, state legislative relations, bond financing,
  public communications etc.
• “IOM recommendation on the
  creation of a Scientific Advisory Board to provide counsel on such
  issues as funding priorities and portfolio strategy will be
  implemented by staff
• “IOM recommendations on
  Intellectual Property will be referred to the agency’s IP
  subcommittee which will review and report back to the full board
  with options and recommendations
• “IOM recommendations on
  Sustainability: Chair, working with the President, will develop a
  plan to address this and present to the Board when ready

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/MHSytXHG-zU/stem-cell-agency-adds-fresh-details-to.html

The California stem cell agency is
planning an editorial road show with major California newspapers to
explain its new plan to deal with the recommendations of the
Institute of Medicine(IOM) for major changes at the agency.

“The opportunity is ripe.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/sN7GVoQPGjA/california-stem-cell-agency-to-pitch.html

The journal Nature today said on its
web site that the California stem cell agency plans to make a “few
changes” in response to a critical report from the Institute of
Medicine(IOM).

"Other IOM recommendations were only
indirectly addressed by (CIRM Chairman J.T.) Thomas’ plan. The IOM report had stated
that the board should restrict itself to an 'oversight' role
rather than an 'operational' role. Thomas’s recommendations
instead described ways to avoid overlapping duties. His own role as
chair is to handle 'external affairs' whereas CIRM’s president
will be to handle scientific and internal affairs."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/JU2zXAO4Q1Q/nature-on-iom-and-california-stem-cell.html

Here is the roll call vote yesterday on the plan to deal with the findings of the Institute of Medicine
concerning the California stem cell agency. The vote was 23-0 with
one abstention. The board has 29 seats. Not all board members were in attendance,
and it is not entirely clear whether all the board members in attendance
voted. Among other things, the plan calls for members with links to
institutions that could benefit from CIRM awards to voluntarily refrain from
voting on any applications for funding – not just those to their
institutions. The roll call was provided by a spokesman for the
agency.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DYyBzk0Er5g/roll-call-vote-on-thomas-plan-dealing.html

The $3 billion California stem cell
agency seemed all but invisible this morning in terms of mainstream
media coverage.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/8q4FDQb-BUk/meager-meager-coverage-of-yesterdays.html

Directors of the $3 billion California
stem cell agency today approved a far-reaching plan aimed at resolving long-standing
conflict of interest issues involving the agency's governing board
and also at helping to maintain credibility with the public.

Jonathan Thomas CIRM photo

“This is one of those times that we must move forward and compromise.” 

• Have 13 members of the 29-member board
  refrain from voting on specific grant applications. The 13 would be from institutions that could benefit from CIRM grants. They would be
  allowed to participate in discussions. Thomas said this would deal
  with financial conflict of interest questions. 
• Increase industry participation of
  industry in grant application review and step up business involvement
  internally at CIRM, including development of RFAs.
• Redirect all scientific appeals to
  staff to evaluate for possible re-review before they go to the full
  board.
• Move “programmatic” review of
  grants to public sessions of the full board instead of being held
  behind closed doors during grant review sessions. Patient advocate
  directors now sitting on the grant review group would no longer be
  allowed to vote during the closed-door review sessions, but they
  could participate in the discussion.

It appears, however, that the Thomas
plan would do little to deal with the dual-executive problems identified
by the IOM.

 "It looks like
the message is finally getting through to California's stem cell
agency board....
Part of what is driving the new
approach is the realization that CIRM will need to find a new source
of funding -- possibly going back to the voters -- if it is to
continue.  As Thomas told the board today, 'If we don't
have credibility, we won't have a chance of sustaining the agency.'"

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Phybdqb0SV0/iom-california-stem-cell-directors.html

Jan. 25, 2013 A new study from Boston University School of Medicine (BUSM) shows that tissues derived from induced pluripotent stem (iPS) cells in an experimental model were not rejected when transplanted back into genetically identical recipients. The study, published online in Cell Stem Cell, demonstrates the potential of utilizing iPS cells to develop cell types that could offer treatment for a wide range of conditions, including diabetes, liver and lung diseases, without the barrier of immune rejection.

Ashleigh Boyd, DPhil, and Neil Rodrigues, DPhil, the study's senior authors, are assistant professors of dermatology at BUSM and researchers at the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC). They also are lead investigators at the National Institutes of Health's Center of Biomedical Research Excellence (COBRE) at Roger Williams Medical Center, a clinical and research affiliate of BUSM.

iPS cells can be developed from adult cell types, such as skin or blood, by returning them to a stem cell state using genetic manipulation. iPS cells are capable of maturing (differentiating) into all the specific cell types in the body, making them a powerful tool for biological research and a source of tissues for transplantation based therapies. Given that iPS cells can be made in a patient-specific manner, there should be great potential for them to be transplanted back into the same patient without rejection. Yet a study published in Nature in 2011 demonstrated that iPS cells transplanted in the stem cell state were rejected in genetically identical recipients.

"The Nature study provocatively suggested that tissues derived from patient-specific iPS cells may be immunogenic after transplantation. However, it never directly assessed the immunogenicity of the therapeutically relevant cell types that could be utilized in regenerative medicine and transplantation," said Rodrigues.

The BUSM researchers evaluated this matter by taking adult cells from an experimental model and deriving iPS cells from them. They then differentiated the iPS cells into three cell types: neuronal (nerve); hepatocytes (liver); and endothelial (blood vessel lining) cells. These three cell types represent each of the three germ layers present during embryonic development -- mesoderm, ectoderm and endoderm. Cells from these layers differentiate and ultimately develop into the body's tissue and organ systems. Using experiments to mirror the potential clinical use of patient-specific iPS cells in cell therapy, the team transplanted each of the differentiated cells into a genetically identical experimental model and found no signs of an elevated immune response or indications of rejection.

The study results suggest that using patient-specific iPS cells should overcome issues of immune rejection in transplantation, which will be a significant problem for potential embryonic stem cell-derived therapies. Immune rejection in transplantation is treated clinically by immunosuppressive drugs but they can have serious side-effects, including the risk of developing cancer.

"If the use of immunosuppressive drugs can be avoided, as may be the case for patient-specific iPS cell based therapies, it would be preferable. Our results are very promising and future work should be directed at assessing whether tissues derived from human iPS cells will similarly lack immunogenicity," said Boyd.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The rest is here:
Potential of differentiated iPS cells in cell therapy without immune rejection